Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma

• Status: Withdrawn
• Trial end date: 2021-01-21

Summary

The purpose of this study is to test the efficacy, safety, and tolerability of the combination of chemotherapy treatment, which could be either Cisplatin or carboplatin and etoposide, and the research study drug, Pembrolizumab (also known as MK-3475) in patients with high grade neuroendocrine carcinomas of the gastroenteropancreatic system or lung who are chemotherapy naïve. The chemotherapy treatment you receive will be either Cisplatin or carboplatin and etoposide. the participant's doctor will discuss this choice with you and determined which chemotherapy treatment is best for you.

• Phase: Phase 2

Details

• Lead Sponsor: Ochsner Health System
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Carboplatin; Cisplatin; Etoposide; Pembrolizumab